Ch 10, 38: Chest and Respiratory Issues Flashcards
Severe allergic reaction with rapid onset
anaphylaxis
patho of anaphylaxis
Immune system produces IgE antibodies that is normally not toxic and antibodies
Antibodies are stored for future exposure and releases histamine
Histamine flushing, urticaria, angioedema, hypotension, and bronchoconstriction
Occurs within seconds/minutes of exposure
Dx made by objective findings
common triggers for anaphylaxis
seafood
latex
drugs
eggs
insects
nuts
mild clinical manifestations of anaphylaxis
Warmth,
tingling,
mouth fullness,
nasal congestion,
periorbital swelling,
sneezing,
eye tearing,
pruritis
moderate clinical manifestations of anaphylaxis
Flushing,
warmth,
anxiety,
itching,
dyspnea,
cough,
wheezing
severe clinical manifestations of anaphylaxis
Bronchospasm,
laryngeal edema,
severe dyspnea,
cyanosis,
hypotension,
dysphagia,
abdominal cramping,
vomiting,
diarrhea,
seizures
prevention of anaphylaxis
Strict avoidance of potential allergen
Carry and administer epi - Teach back method
Always carry an emergency kit
Screen for allergies
Wear medical alert bracelet
Desensitization
medical management of anaphylaxis
ABC support
-Ensure airway patency
-Oxygenation
-Epi 1:1000 dilution first line treatment
-Antihistamines and corticosteroids
-IVF
-Pressors
-Aminophylline to improve breathing/airway
Be aware of rebound reaction 4-10 hours after initial reaction
nursing management of anaphylaxis
Assess for s/s
Prompt notification to provider or EMS
Prepare for emergency procedures
–ET intubation may be difficult; prepare for cricothyrotomy
Education on prevention
Proper management of chronic conditions (asthma)
Be aware of adverse effects from epi
Obstruction of the pulmonary artery by a thrombus/thrombi that originates in the venous system
pulmonary embolism
what in a pulmonary embolism leads to impaired gas exchange
The embolus travels through venous systems and into the pulmonary circulation and cuts off the blood supply to the alveoli
what in a pulmonary embolism lead to decreased cardiac output
Obstruction of pulmonary causes increases pressure and puts a strain on the right ventricle
causes of PE
clot,
air,
fat,
amniotic fluid,
tumor cells,
bacteria (vegetation)
injected particles
What is virchow’s triad (PE)
blood venous stasis
changes in coagulation
damage to the vessel
third leading cause of death in a hospital
pulmonary embolism
risk factors for PE
Acute medical illness (a-fib, etc.)
Major surgery
Trauma
Cancer (including therapies)
Hx of VTE
Obesity
Immobility for more than 2 days
Age >40
Hypercoagulable conditions
Prolonged mechanical ventilation
Neuromuscular paralytic use
Central venous catheters
Severe sepsis
Heparin-induced thrombocytopenia
Oral contraceptive use and estrogen therapy
Pregnancy
Tobacco use
Long bone fractures
clinical manifestations of PE
Dyspnea
Pleuritic chest pain - have to rule out MI
Anxiety; feeling of impending doom
Syncope
Cough
Hemoptysis
Palpitations
Tachypnea
Crackles
Tachycardia
Presence of S4
Can be asymptomatic
Death can occur within hours
lab and diagnostics for PE
- chest x-ray
- ABGs - show hypoxemia and hypocapnia (from tachypnea)
- D-dimer - occurs from fibrin lysis; normal <0.4 mcg/mL; elevated with thromboembolic events
- ECG - to assess right ventricle function
- doppler ultrasonography - displays DVT -cause of PE
- V/Q scan - comparison of ventilation and perfusion
- CTPA - standard for detecting PE - visualizes pulmonary angiography with IV contrast
prevention of PE
Prevent DVT!!
-Active leg exercises
-Early ambulation
-Elastic compression stockings or electronic compression devices (SCD)
-Prophylactic anticoagulation with expected immobilization
–Low dose heparin
–Low-molecular weight heparin
-Patient education
-Smoking cessation
-Avoid crossing legs
-Avoid long periods of immobility
-Prevent PE with traveling
-Stay hydrated
Early recognition of problems!!!
emergency management of PE
- oxygen
- IVF
- Perfusion scans, ABGs, CT, angiogram, ECG, echo
-Vasopressors or inotropes
-Dig, IV diuretics, antiarrhythmics if appropriate
-Labs
–Coagulation studies (PT, PTT, INR, d-dimer)
–Serum electrolytes
–CBC
-Possible intubation and mechanical ventilation
-Indwelling catheter
-IV morphine or sedatives
-IV thrombolytics
-Anticoagulants
anticoagulant therapy for PE (heparin)
PREVENTS does not DISSOLVE
Continuous heparin infusion
-Goal: Therapeutic PTT to reduce risk and recurrence of PE
-Dosed by weight
-Initial bolus IV dose 80 units/kg then a continuous infusion of 18 units/kg/hr
-Maintain PTT 1.5-2.5 times the control (21-35 sec; for heparin therapy 50-70 sec)
-Titrated based on PTT (drawn Q6 hours)
-Monitor and report s/s of bleeding
-Have antidote available
LMWH
-For hemodynamically stable clients (with stable PE)
-No need to monitor labs
Anticoagulant therapy for PE (Warfarin)
Prevent does NOT dissolve
Warfarin
-Can be added to IV therapy (bridge therapy)
-Monitor INR (normal 1, goal with warfarin is 2-3)
-The higher the INR the longer it takes for blood to clot
-Have antidote available
-Monitor amount of vit K in diet
Other orals
-Apixaban (Eliquis), dabigatran (Pradaxa), rivaroxaban (Xarelto)
antidote for heparin
protamine sulfate
antidote for warfarin
Vit K